THE SCIENCE

BOOKS, ARTICLES, PUBLICATIONS, AND RESEARCH


Clinical Autonomic Dysfunction
Measurement, Indications, Therapies, and Outcomes

This book presents the concepts underlying the measurement of parasympathetic and sympathetic (P&S) activity in the autonomic nervous system and the application of these measurements in the development of therapeutic guidelines for treating dysfunctions in these processes. It provides an overview of the anatomy, physiology, and biochemistry of the autonomic nervous system; details general clinical applications of P&S monitoring that are independent of specialty or disease; presents the pathophysiology of P&S dysfunction in specific disorders, expected test results, therapeutic options, and expected outcomes; and includes case studies and longitudinal studies that demonstrate the major concepts for the common diseases for which P&S monitoring is recommended. Clinical Autonomic Dysfunction enables clinicians to improve patient outcomes by identifying and treating clinical problems related to autonomic nervous system disorders.


Clinical Autonomic and Mitochondrial Disorders
Diagnosis, Prevention, and Treatment for Mind-Body Wellness

This book establishes and specifies a rigorously scientific and clinically valid basis for nonpharmaceutical approaches to many common diseases and disorders found in clinical settings. It includes lifestyle and supplement recommendations for beginning and maintaining autonomic nervous system and mitochondrial health and wellness. The book is organized around a six-pronged mind-body wellness program and contains a series of clinical applications and frequently asked questions. The physiologic need and clinical benefit and synergism of all six aspects working together are detailed, including the underlying biochemistry, with exhaustive references to statistically significant and clinically relevant studies. The book covers a range of clinical disorders, including anxiety, arrhythmia, atherosclerosis, bipolar disease, dementia, depression, fatigue, fibromyalgia, heart diseases, hypertension, mast cell disorder, migraine, and PTSD. Clinical Autonomic and Mitochondrial Disorders: Diagnosis, Prevention, and Treatment for Mind-Body Wellness is an essential resource for physicians, residents, fellows, medical students, and researchers in cardiology, primary care, neurology, endocrinology, psychiatry, and integrative and functional medicine. It provides therapy options to the indications and diagnoses published in the book 
Clinical Autonomic Dysfunction.


Autonomic Nervous System Monitoring: Failed Clinical Utility

The Importance of Parasympathetic Monitoring

As the title may suggest the use of ANS monitoring may not lead to accurate clinical diagnoses and treatment for many ailments using other technologies available to healthcare professionals. What is missing from this title is the fact that without measuring the Parasympathetic nervous system in total and independently, a correct diagnosis would not be provided. This problem exists in the industry through HRV (Heart Rate Variability) btb-readings, such as btb-Blood Pressure, Pulse Wave Velocity, and more.



THE IMPORTANCE OF ALA IN MAINTAINING ANTIOXIDANT BALANCE

OXIDATIVE STRESS: Alpha Lipoic Acid & Coenzyme Q-10

Oxidative stress is a process whereby, Free Radicals that are produced by the body, cause injury to the tissues themselves; especially one of the most important organelles in the cell.  The organelle that produces energy:  The Mitochondria.  Oxidation is the process of burning, think of fire, or rusting, think of iron. 


CARDIAC AUTONOMIC TESTING AND DIAGNOSING HEART DISEASE. “A CLINICAL PERSPECTIVE” 1 OF 2

Coronary heart disease (CHD) is a major health concern, affecting nearly half the middle-age population and responsible for nearly one-third of all deaths. Clinicians have responsibilities beyond diagnosing CHD, including risk stratification of patients for major adverse cardiac events (MACE), modifying the risks and treating the patient. In this first of a two-part review, identifying risk factors is reviewed, including more potential benefit from autonomic testing.

CARDIAC AUTONOMIC TESTING AND TREATING HEART DISEASE. “A CLINICAL PERSPECTIVE” 2 OF 2

Coronary heart disease (CHD) is a major health concern, affecting nearly half the middle-age population and responsible for nearly one-third of all deaths. Clinicians have several major responsibilities beyond diagnosing CHD, such as risk stratification of patients for major adverse cardiac events (MACE) and treating risks, as well as the patient. This second of a two-part review series discusses treating risk factors, including autonomic dysfunction, and expected outcomes.


IMPROVED PATIENT OUTCOMES BY NORMALIZING SYMPATHOVAGAL BALANCE: DIFFERENTIATING SYNCOPE—PRECISE SUBTYPE DIFFERENTIATION LEADS TO IMPROVED OUTCOMES

Syncope is difficult to definitively diagnose, even with tilt-table testing and beat-to-beat blood pressure measurements, the gold-standard. Both are qualitative, subjective assessments. There are subtypes of syncope associated with autonomic conditions for which tilt-table testing is not useful. Heart rate variability analyses also include too much ambiguity.


NONINVASIVE MONITORING OF THE AUTONOMIC NERVOUS SYSTEM AND HEMODYNAMICS OF PATIENTS WITH BLUNT AND PENETRATING TRAUMA

To describe early effects of sympathetic (SNS) and parasympathetic nervous system (PSNS) activities measured by heart rate (HR) and respiratory rate variabilities simultaneously with noninvasive hemodynamic patterns in patients with blunt and penetrating trauma.


ROUTINE MEASUREMENTS OF CARDIAC PARASYMPATHETIC AND SYMPATHETIC NERVOUS SYSTEMS ASSISTS IN PRIMARY AND SECONDARY RISK STRATIFICATION AND MANAGEMENT OF CARDIOVASCULAR CLINIC PATIENTS

Reviewing our studies of the ease and importance of Parasympathetic and Sympathetic (P&S) measures in managing cardiovascular patients.


Differential Effects of Adrenergic Antagonists (Carvedilol vs. Metoprolol) on Parasympathetic and Sympathetic Activity:  A Comparison of Measures
1 of 2

Cardiovascular autonomic neuropathy (CAN) is recognized as a significant health risk. Specific and sensitive measures of CAN are needed for early identification and treatment to avoid complications, preferably in the preclinical state.

Differential Effects of Adrenergic Antagonists (Carvedilol vs. Metoprolol) on Parasympathetic and Sympathetic Activity:  A Comparison of Clinical Results
2 of 2

Cardiovascular autonomic neuropathy (CAN) is recognized as a significant health risk, correlating with risk of heart disease, silent myocardial ischemia or sudden cardiac death. Beta-blockers are often prescribed to minimize risk.


(r)ALPHA LIPOIC ACID IS A SAFE, EFFECTIVE PHARMACOLOGIC THERAPY OF CHRONIC ORTHOSTATIC HYPOTENSION ASSOCIATED WITH LOW SYMPATHETIC TONE

Chronic orthostatic hypotension (OH), affecting 10 to 30% of the elderly, is associated with falls, and increased morbidity and mortality. Current pharmacologic therapy can cause or worsen hypertension and fluid retention. (r)α lipoic acid (ALA), a powerful natural antioxidant, avoids those complications and may assist management of chronic neurogenic orthostatic hypotension (NOH).


Ranolazine Improves Autonomic Balance In Heart Failure When Added to Guideline Driven Therapy

The effect of ranolazine (RAN) on cardiac autonomic balance in congestive heart failure (CHF) was studied.


Ranolazine Preserves and Improves
Left Ventricular Ejection Fraction and Autonomic Measures
When Added to Guideline-Driven Therapy in Chronic Heart Failure

Ranolazine (RAN) reduces cardiac sodium channel 1.5’s late sodium current in congestive heart failure (CHF), reducing myocardial calcium overload, potentially improving left ventricular (LV) function. RAN blocks neuronal sodium channel 1.7, potentially altering parasympathetic and sympathetic (P&S) activity. The effects of RAN on LV ejection fraction (LVEF) and P&S function in CHF were studied.


Ranolazine Therapy Reduces Non-ST-Segment-Elevation Myocardial Infarction and Unstable Angina in Coronary Disease Patients with Angina

High sympathetic tone and cardiac autonomic neuropathy (CAN) are associated with major adverse cardiac events (MACE). We have shown ranolazine (RAN) improves autonomic function. RAN was introduced to 51 successive anginal CD patients (RANCD). A control group of 54 successive nonanginal CD patients (NORANCD) continued baseline therapy. 


Routine Measurements of Cardiac Parasympathetic and Sympathetic Nervous Systems Assists in Primary and Secondary Risk Stratification and Management of Cardiovascular Clinic Patients

Reviewing our studies of the ease and importance of Parasympathetic and Sympathetic (P&S) measures in managing cardiovascular patients.


Autonomic Mechanisms and Therapeutic Implications of
Postural Diabetic Cardiovascular Abnormalities

Reviewing our studies of the ease and importance of Parasympathetic and Sympathetic (P&S) measures in managing cardiovascular patients.


HOME

Physio PS © 2020 All Rights Reserved. The material and information provided by Physio PS is for general information purposes only. You should not rely upon this material or information for basis of making healthcare, treatment or diagnosis decisions. While Physio PS strives to provide the most correct and up to date information and data, Physio PS makes no representations or warranties of any kind, expressed or implied about the completeness, accuracy, reliability, suitability or availability with respect to the information, products, services or related graphics contained.  Any reliance placed on such material is therefore strictly at your own risk. Reporting Information is supplied under license by NCRC LLC.
* ‘RFa’ is known to be a measure of Parasympathetic activity and ‘LFa’ is known to be a measure of Sympathetic activity, based on reference: Colombo J, Arora RR, DePace NL, Vinik AI, Clinical Autonomic Dysfunction: Measurement, Indications, Therapies, and Outcomes. Springer Science + Business Media, New York, NY; 2014.